Home › Companies › AXSOME THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AXSOME THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2025: 4 items on AXSOME THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025: 1 elected · 3 approved.
Significant dissent: 1 director (22.8% against); 1 equity or compensation plan (25.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AXSOME THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are AXSOME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Roger A. Jeffs, Ph.D. | 27,307,185 | -- | -- | 8,050,959 | 6,010,496 | 77% | Elected | — |
| 2. Approval of the Company's 2025 Long-Term Incentive Plan | 26,403,625 | 8,893,068 | 61,451 | -- | 6,010,496 | 75% | Approved | — |
| 3. Ratification of Appointment of Deloitte & Touche LLP | 40,849,740 | 225,677 | 293,223 | -- | 0 | 99.5% | Approved | — |
| 4. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers | 34,776,343 | 528,199 | 53,602 | -- | 6,010,496 | 99% | Approved | — |
Source: AXSOME THERAPEUTICS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
346 asset managers disclosed a vote on at least one AXSOME THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: Election of Director: Roger Jeffs, Ph.D.
AXSOME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roger A. Jeffs, Ph.D.”): 27,307,185 for, 8,050,959 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following director to serve as a Class I director until the 2028 annual meeting of stockholders and until their successor is duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 94 asset managers below reported 8,265,347 for, 3,496,726 withheld, 0 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,805,597 | 0 | 0 | 311 | For |
| Fidelity | 1,568,223 | 0 | 0 | 0 | For |
| BlackRock | 992,353 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 742,065 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 705,954 | Withhold |
| Invesco | 0 | 0 | 0 | 689,907 | Withhold |
| TIAA | 0 | 0 | 0 | 381,193 | Withhold |
| Charles Schwab | 340,860 | 0 | 0 | 0 | For |
| Putnam | 200,650 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 199,412 | Withhold |
| Loomis Sayles | 0 | 0 | 0 | 162,529 | Withhold |
| Waddell & Reed | 0 | 0 | 0 | 139,244 | Withhold |
| Principal | 129 | 0 | 0 | 137,700 | Withhold |
| Equitable | 91,653 | 0 | 0 | 45,190 | Mixed |
| Hartford | 95,992 | 0 | 0 | 0 | For |
| Jackson National | 60,290 | 0 | 0 | 28,911 | Mixed |
| Aberdeen | 0 | 0 | 0 | 81,916 | Withhold |
| Lincoln Financial | 27,100 | 0 | 0 | 44,031 | Mixed |
| DWS | 0 | 0 | 0 | 65,679 | Withhold |
| First Trust | 0 | 0 | 0 | 64,278 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 62,747 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 0 | 0 | 0 | 61,282 | Withhold |
| Voya | 0 | 0 | 0 | 56,802 | Withhold |
| CARILLON SERIES TRUST | 0 | 0 | 0 | 55,770 | Withhold |
| Nuveen | 0 | 0 | 0 | 48,397 | Withhold |
Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
75% Approved · of votes cast
Description as filed by funds: To approve the Company's 2025 Long-Term Incentive Plan.
AXSOME THERAPEUTICS INC.’s own tally for this item (“2. Approval of the Company's 2025 Long-Term Incentive Plan”): 26,403,625 for, 8,893,068 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve the 2025 Long-Term Incentive Plan.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 93 asset managers below reported 8,316,783 for, 3,394,090 against, 25,750 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,805,908 | 0 | 0 | 0 | For |
| Fidelity | 1,568,223 | 0 | 0 | 0 | For |
| BlackRock | 992,353 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 742,065 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 705,954 | 0 | 0 | Against |
| Invesco | 0 | 689,907 | 0 | 0 | Against |
| TIAA | 0 | 381,193 | 0 | 0 | Against |
| Charles Schwab | 340,860 | 0 | 0 | 0 | For |
| Putnam | 0 | 200,650 | 0 | 0 | Against |
| T. Rowe Price | 187,774 | 11,638 | 0 | 0 | Mixed |
| Loomis Sayles | 162,529 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 139,244 | 0 | 0 | Against |
| Principal | 129 | 137,700 | 0 | 0 | Against |
| Equitable | 91,653 | 45,190 | 0 | 0 | Mixed |
| Hartford | 95,992 | 0 | 0 | 0 | For |
| Jackson National | 0 | 89,201 | 0 | 0 | Against |
| Aberdeen | 0 | 81,916 | 0 | 0 | Against |
| Lincoln Financial | 0 | 71,131 | 0 | 0 | Against |
| DWS | 0 | 65,679 | 0 | 0 | Against |
| First Trust | 0 | 64,278 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 62,747 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 61,282 | 0 | 0 | 0 | For |
| Voya | 0 | 56,802 | 0 | 0 | Against |
| CARILLON SERIES TRUST | 0 | 55,770 | 0 | 0 | Against |
| Nuveen | 0 | 48,397 | 0 | 0 | Against |
Showing the 25 largest of 93 asset managers. All 93 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 97.4% for (June 7, 2024 meeting) ▲ 1.1 pts
Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers.
AXSOME THERAPEUTICS INC.’s own tally for this item (“4. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 34,776,343 for, 528,199 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of AXSOME THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Section 14a Executive Compensation” (2 managers, 19 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,805,597 | 311 | 0 | 0 | For |
| Fidelity | 1,568,223 | 0 | 0 | 0 | For |
| BlackRock | 992,353 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 742,065 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 705,954 | 0 | 0 | 0 | For |
| Invesco | 689,907 | 0 | 0 | 0 | For |
| TIAA | 381,193 | 0 | 0 | 0 | For |
| Charles Schwab | 340,860 | 0 | 0 | 0 | For |
| Putnam | 200,650 | 0 | 0 | 0 | For |
| T. Rowe Price | 199,412 | 0 | 0 | 0 | For |
| Loomis Sayles | 162,529 | 0 | 0 | 0 | For |
| Waddell & Reed | 139,244 | 0 | 0 | 0 | For |
| Principal | 137,829 | 0 | 0 | 0 | For |
| Equitable | 136,843 | 0 | 0 | 0 | For |
| Hartford | 95,992 | 0 | 0 | 0 | For |
| Jackson National | 89,201 | 0 | 0 | 0 | For |
| Aberdeen | 81,916 | 0 | 0 | 0 | For |
| Lincoln Financial | 71,131 | 0 | 0 | 0 | For |
| DWS | 65,679 | 0 | 0 | 0 | For |
| First Trust | 64,278 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,747 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 61,282 | 0 | 0 | 0 | For |
| Voya | 56,802 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 55,770 | 0 | 0 | 0 | For |
| Nuveen | 48,397 | 0 | 0 | 0 | For |
Fund voting reports, all 93 managers: 11,756,450 for, 1,463 against, 3,867 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 2,826,708 | 0 | 0 | 0 | For |
| BVF INC/IL | 1,690,221 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,032,719 | 0 | 0 | 0 | For |
| BlackRock | 988,520 | 0 | 0 | 0 | For |
| Fidelity | 948,566 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 941,646 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 815,176 | 0 | 0 | 0 | For |
| Invesco | 785,982 | 0 | 0 | 0 | For |
| Wellington | 481,123 | 0 | 0 | 0 | For |
| State Street | 451,462 | 0 | 0 | 0 | For |
| Nuveen | 434,480 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 423,440 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 399,200 | 0 | 0 | 0 | For |
| Charles Schwab | 340,922 | 0 | 0 | 0 | For |
| Man Group plc | 334,690 | 0 | 0 | 0 | For |
| T. Rowe Price | 323,320 | 0 | 0 | 0 | For |
| 1832 Asset Management L.P. | 320,700 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 300,000 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 297,444 | 0 | 0 | 0 | For |
| Putnam | 285,482 | 0 | 0 | 0 | For |
| Woodline Partners LP | 275,521 | 0 | 0 | 0 | For |
| Loomis Sayles | 248,481 | 0 | 0 | 0 | For |
| Northern Trust | 237,762 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 200,374 | 29 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 197,565 | 0 | 0 | 0 | For |
Institutional-manager reports, all 274 managers: 18,430,043 for, 257,875 against, 10,899 abstained, 11 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.5% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.
AXSOME THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of Deloitte & Touche LLP”): 40,849,740 for, 225,677 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of AXSOME THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 556 for).
The 93 asset managers below reported 11,738,695 for, 18,973 against, 3,867 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,805,908 | 0 | 0 | 0 | For |
| Fidelity | 1,568,223 | 0 | 0 | 0 | For |
| BlackRock | 992,353 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 742,065 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 705,954 | 0 | 0 | 0 | For |
| Invesco | 689,907 | 0 | 0 | 0 | For |
| TIAA | 381,193 | 0 | 0 | 0 | For |
| Charles Schwab | 340,860 | 0 | 0 | 0 | For |
| Putnam | 200,650 | 0 | 0 | 0 | For |
| T. Rowe Price | 199,412 | 0 | 0 | 0 | For |
| Loomis Sayles | 162,529 | 0 | 0 | 0 | For |
| Waddell & Reed | 139,244 | 0 | 0 | 0 | For |
| Principal | 137,829 | 0 | 0 | 0 | For |
| Equitable | 136,843 | 0 | 0 | 0 | For |
| Hartford | 95,992 | 0 | 0 | 0 | For |
| Jackson National | 89,201 | 0 | 0 | 0 | For |
| Aberdeen | 81,916 | 0 | 0 | 0 | For |
| Lincoln Financial | 71,131 | 0 | 0 | 0 | For |
| DWS | 65,679 | 0 | 0 | 0 | For |
| First Trust | 64,278 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,747 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 61,282 | 0 | 0 | 0 | For |
| Voya | 56,802 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 55,770 | 0 | 0 | 0 | For |
| Nuveen | 48,397 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. All 93 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,216,759 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.73% |
| 2 | Fidelity | 3.19% |
| 3 | BlackRock | 2.02% |
| 4 | MUTUAL FUND SERIES TRUST | 1.51% |
| 5 | Delaware/Macquarie | 1.43% |
| 6 | Invesco | 1.40% |
| 7 | TIAA | 0.77% |
| 8 | Charles Schwab | 0.69% |
| 9 | Putnam | 0.41% |
| 10 | T. Rowe Price | 0.41% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RTW INVESTMENTS, LP | 5.74% |
| 2 | BVF INC/IL | 3.43% |
| 3 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 2.10% |
| 4 | BlackRock | 2.01% |
| 5 | Fidelity | 1.93% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.91% |
| 7 | Fairmount Funds Management LLC | 1.66% |
| 8 | Invesco | 1.60% |
| 9 | Wellington | 0.98% |
| 10 | State Street | 0.92% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Herriot Tabuteau, M.D. | 9,357,727 | 19.01% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Antecip Capital LLC | 7,344,500 | 14.92% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Vanguard Group | 3,876,942 | 7.88% | Form 13F, quarter ended March 31, 2025 |
| BlackRock | 3,524,411 | 7.16% | Form 13F, quarter ended March 31, 2025 |
| RTW Investments, LP | 1,516,903 | 3.08% | Schedule 13G, filed August 14, 2025 |
| FMR (Fidelity) | 1,247,231 | 2.53% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 934,853 | 1.90% | Form 13F, quarter ended March 31, 2025 |
| State Street | 906,020 | 1.84% | Form 13F, quarter ended March 31, 2025 |
| Invesco | 857,001 | 1.74% | Form 13F, quarter ended March 31, 2025 |
| Wellington Management | 703,279 | 1.43% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 49,216,759 shares outstanding, as reported by AXSOME THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At AXSOME THERAPEUTICS INC.'s shareholder meeting held June 6, 2025, in the 2024-2025 proxy season, 346 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,519 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the compensation of our named executive officers. — AXSOME THERAPEUTICS INC.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AXSOME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AXSOME THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AXSOME THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “AXSOME THERAPEUTICS (AXSM) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/axsome-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.